Evidence map›Paper›PMID 32283627›Full record

ArticleCancers2020

Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort.

Elise de Savornin Lohman, Tessa de Bitter, Rob Verhoeven, Lydia van der Geest, Jeroen Hagendoorn, Nadia Haj Mohammad, Freek Daams, Heinz-Josef Klümpen, Thomas van Gulik, Joris Erdmann and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. SevereCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Elise de Savornin LohmanDepartment of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Tessa de BitterDepartment of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Rob VerhoevenDepartment of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.ORCID 0000-0001-9678-1611
Lydia van der GeestDepartment of Research, Netherlands Comprehensive Cancer Organization, 3501 DB Utrecht, The Netherlands.
Jeroen HagendoornDepartment of Surgery, Utrecht University Medical Center, 3508 GA Utrecht, The Netherlands.
Nadia Haj MohammadDepartment of Medical Oncology, Utrecht University Medical Center, Utrecht University, 3508 GA Utrecht, The Netherlands.
Freek DaamsDepartment of Surgery, Amsterdam University Medical Centers, VU University, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands.
Heinz-Josef KlümpenDepartment of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100 DD Amsterdam, The Netherlands.
Thomas van GulikDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100DD Amsterdam, The Netherlands.
Joris ErdmannDepartment of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100DD Amsterdam, The Netherlands.
Marieke de BoerDepartment of Surgery, Section of HPB-Surgery and Liver Transplantation, University Medical Center Groningen, 97700 RB Groningen, The Netherlands.
Frederik HoogwaterDepartment of Surgery, Section of HPB-Surgery and Liver Transplantation, University Medical Center Groningen, 97700 RB Groningen, The Netherlands.ORCID 0000-0002-3320-7185
Bas Groot KoerkampDepartment of Surgery, Erasmus MC, 3000 CB Rotterdam, The Netherlands.
Andries BraatDepartment of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Joanne VerheijDepartment of Pathology, Amsterdam University Medical Center, 1100 DD Amsterdam, The Netherlands.
Iris NagtegaalDepartment of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Cornelis van LaarhovenDepartment of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Peter van den BoezemDepartment of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Rachel van der PostDepartment of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Philip de ReuverDepartment of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
Radboud University Nijmegen · NLAmsterdam University Medical Centers · NLUniversity Medical Center Groningen · NLUtrecht University · NLErasmus MC · NLLeiden University Medical Center · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

ADP 55695817
6 · The paper itself

Abstract

Gallbladder cancer (GBC) is rare in Western populations and data about treatment and outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement using population-based data from a low-incidence country. GBC patients diagnosed between 2005 and 2016 with GBC were identified from the Netherlands Cancer Registry. Patients were grouped according to time period (2005-2009/2010-2016) and disease stage. Trends in treatment and overall survival (OS) were analyzed. In total 1834 patients were included: 661 (36%) patients with resected, 278 (15%) with non-resected non-metastatic, and 895 (49%) with metastatic GBC. Use of radical versus simple cholecystectomy (12% vs. 26%,

Indexed as

chemotherapycohort studiesepidemiologygallbladder neoplasmssurgery

Identifiers

PMID32283627
PMCPMC7226578
OpenAlexW3015643346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.